Kazia Therapeutics (KZIA) Retained Earnings (2017 - 2025)
Kazia Therapeutics (KZIA) has disclosed Retained Earnings for 4 consecutive years, with -$86.3 million as the latest value for Q2 2025.
- For the quarter ending Q2 2025, Retained Earnings fell 13.8% year-over-year to -$86.3 million, compared with a TTM value of -$86.3 million through Jun 2025, down 13.8%, and an annual FY2025 reading of -$87.4 million, down 15.73% over the prior year.
- Retained Earnings was -$86.3 million for Q2 2025 at Kazia Therapeutics, down from -$75.9 million in the prior quarter.
- Across five years, Retained Earnings topped out at $2.5 million in Q2 2023 and bottomed at -$86.3 million in Q2 2025.
- Average Retained Earnings over 4 years is -$39.5 million, with a median of -$37.1 million recorded in 2022.
- The sharpest move saw Retained Earnings skyrocketed 42.4% in 2023, then tumbled 3183.99% in 2024.
- Year by year, Retained Earnings stood at $1.7 million in 2022, then surged by 42.4% to $2.5 million in 2023, then plummeted by 3183.99% to -$75.9 million in 2024, then fell by 13.8% to -$86.3 million in 2025.
- Business Quant data shows Retained Earnings for KZIA at -$86.3 million in Q2 2025, -$75.9 million in Q2 2024, and $2.5 million in Q2 2023.